[1]王晓娇,练孝春,刘正人.埃兹蛋白在乳腺癌中的表达及其临床意义[J].医学信息,2019,32(21):88-91.[doi:10.3969/j.issn.1006-1959.2019.21.027]
　WANG Xiao-jiao,LIAN Xiao-chun,LIU Zheng-ren.Expression of Ezrin in Breast Cancer and Its Clinical Significance[J].Journal of Medical Information,2019,32(21):88-91.[doi:10.3969/j.issn.1006-1959.2019.21.027]
点击复制

埃兹蛋白在乳腺癌中的表达及其临床意义()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年21期
页码:
88-91
栏目:
论著
出版日期:
2019-11-01

文章信息/Info

Title:
Expression of Ezrin in Breast Cancer and Its Clinical Significance
文章编号:
1006-1959（2019）21-0088-04
作者:
王晓娇1; 练孝春1; 刘正人2
（1.芜湖市第一人民医院乳腺外科，安徽 芜湖 241000；2.南昌大学第一附属医院乳腺外科，江西 南昌 330000）
Author(s):
WANG Xiao-jiao1; LIAN Xiao-chun1; LIU Zheng-ren2
(1.Department of Breast Surgery,the First People's Hospital of Wuhu City,Wuhu 241000,Anhui,China;2.Department of Breast Surgery,the First Affiliated Hospital of Nanchang University,Nanchang 330000,Jiangxi,China)
关键词:
乳腺癌; 埃兹蛋白; 侵袭; 转移; 免疫组化
Keywords:
Breast cancer; Ezrin; Invasion; Metastasis; Immunohistochemistry
分类号:
R737.9
DOI:
10.3969/j.issn.1006-1959.2019.21.027
文献标志码:
A
摘要:
目的 通过检测埃兹蛋白在浸润性乳腺癌、乳腺导管内癌及正常乳腺组织中的表达，探究埃兹蛋白在乳腺癌组织中的表达的临床意义。方法 随机选取南昌大学第一附属医院40例浸润性乳腺癌患者及32例乳腺导管内癌患者，另外选择同期来我院健康体检者22例。通过免疫组化链霉亲和素-过氧化物酶法（S-P）法分别检测埃兹蛋白在22例正常乳腺组织、32例乳腺导管内癌组织和40例浸润性乳腺癌组织中的表达，参照病理结果进行分析。结果 埃兹蛋白在40例浸润性乳腺癌的阳性表达率为72.50%、在32例乳腺导管内癌的阳性表达率为40.63%、在正常乳腺组织中的阳性表达率13.64%，浸润性乳腺癌中埃兹蛋白的表达高于其他两种组织，差异具有统计学意义（P＜0.05）；埃兹蛋白在G3期乳腺癌组织中的表达高于在G1~G2期乳腺癌组织中的表达，差异具有统计学意义（P＜0.05）；埃兹蛋白在淋巴结转移患者中的阳性表达率高于在无淋巴结转移的患者中的阳性表达率，差异统计学意义显著（P＜0.01）；埃兹蛋白在＜40岁的患者中的阳性表达率低于在年龄≥40岁的患者中的表达率，差异统计学意义显著（P＜0.01）；埃兹蛋白在PR阳性患者中的阳性表达率低于在PR阴性患者中的表达率，差异具有统计学意义（P＜0.05）；乳腺癌患者中埃兹蛋白的表达与组织学分级、腋窝淋巴结转移及年龄呈正相关（P＜0.05），与PR呈负相关（P＜0.05）；埃兹蛋白在浸润性润腺癌中的表达与乳腺癌临床分期、脉管侵犯、肿瘤大小、患者月经状态以及Her-2、ER、Ki-67的表达无相关性（P＞0.05）。结论 埃兹蛋白在乳腺癌和正常乳腺组织中的表达不同，对判断乳腺肿瘤性质具有重要参考意义；此外，埃兹蛋白能够帮助判断乳腺癌的转移潜能和预后，可能启发乳腺癌新的靶向治疗。
Abstract:
Objective To investigate the clinical significance of ezrin expression in breast cancer tissues by detecting the expression of ezrin in invasive breast cancer, intraductal carcinoma of the breast and normal breast tissue. Methods 40 patients with invasive breast cancer and 32 patients with intraductal carcinoma of the breast in the First Affiliated Hospital of Nanchang University were randomly selected. In addition, 22 healthy subjects were enrolled in our hospital. The expression of ezrin in 22 normal breast tissues, 32 breast ductal carcinoma tissues and 40 invasive breast cancer tissues was detected by immunohistochemical streptavidin-peroxidase (S-P) method. The analysis was performed with reference to the pathological results. Results The positive expression rate of ezrin in 40 cases of invasive breast cancer was 72.50%, the positive expression rate in 32 cases of breast ductal carcinoma was 40.63%, and the positive expression rate in normal breast tissue was 13.64%.The expression of ezrin in invasive breast cancer was higher than that in the other two tissues,the difference was statistically significant (P<0.05); the expression of ezrin in G3 breast cancer tissues was higher than that in G1~G2 breast cancer tissues, the difference was statistically significant (P<0.05); The positive expression rate of ezrin in patients with lymph node metastasis was higher than that in patients without lymph node metastasis, the difference was statistically significant (P<0.01); The positive expression rate of ezrin in patients <40 years old was lower than that in patients aged 40 years or older, the difference was statistically significant (P<0.01); the positive expression of ezrin in PR positive patients the rate was lower than that in PR-negative patients,the difference was statistically significant (P<0.05). The expression of ezrin in breast cancer patients was positively correlated with histological grade, axillary lymph node metastasis and age (P<0.05),negative correlation with PR (P<0.05); expression of ezrin in invasive adenocarcinoma and clinical stage of breast cancer, vascular invasion, tumor size, patient's menstrual status and Her-2, ER, Ki-67 there was no correlation in expression (P>0.05). Conclusion The expression of ezrin in breast cancer and normal breast tissue is different, which has important reference significance for judging the nature of breast tumor. In addition, ezrin can help determine the metastatic potential and prognosis of breast cancer, and may inspire new targets of breast cancer treatment.

参考文献/References:

[1]兰柯,李文翰,徐子森,等.卡培他滨在治疗转移性乳腺癌中作用的Meta分析[J].中国临床药理学与治疗学,2015,11(4):425-429. [2]刘宏,张阳德.Ezrin蛋白与肿瘤转移关系[J].中国现代医学杂志,2009,19(19):952. [3]于兴燕,于东红.Ezrin 蛋白在肿瘤中的研究进展[J].医学综述,2015,36(23):4278-4280. [4]孔界男,周宪春,韩龙哲,等.甲胎蛋白阴性肝细胞癌中埃兹蛋白(ezrin)和SIX1蛋白表达水平的临床病理意义[J].细胞与分子免疫学杂志,2016,14(2):236-239. [5]Penchev VR,Chang YT,Begum A,et al.Ezrin Promotes Stem Cell Properties in Pancreatic Ductal Adenocarcinoma[J].Mol Cancer Res,2019,17(4):929-936. [6]Xie YH,Li LY,He JZ,et al.Heat shock protein family B member 1 facilitates ezrin activation to control cell migration in esophageal squamous cell carcinoma[J].Int J Biochem Cell Biol,2019(112):79-87. [7]Slik K,Kurki S,Korpela T,et al.Ezrin expression combined with MSI status in prognostication of stage Ⅱ colorectal cancer[J].PLoS One,2017,12(9):e0185436. [8]李运华,刘绍华,欧阳坚,等.乳腺癌组织Ezrin、VEGF表达变化及其与临床分期的关系[J].山东医药,2017,57(20):58-59. [9]马小斌,王西京,刘小旭,等.Ezrin在乳腺癌发生发展中的表达及意义[J].现代肿瘤医学,2008,16(3):362-364. [10]Li N,Kong J,Lin Z,et al.Ezrin promotes breast cancer progression by modulating AKT signals [J].Br J Cancer,2019,120(7):703-713. [11]Ghaffari A,Hoskin V,Turashvili G,et al.Intravital imaging reveals systemic ezrin inhibition impedes cancer cell migration and lymph node metastasis in breast cancer[J].Breast Cancer Res,2019,21(1):12. [12]方军.Ezrin蛋白表达与乳腺癌临床病理特征的相关性研究[J].检验医学与临床,2014,11(8):1048-1049. [13]Antelmi E,Cardone RA,Greco MR,et al.ss1 integrin binding phosphorylates ezrin at T567 to activate a lipid raft signalsome driving invadopodia activity and invasion[J].PLoS One,2013,8(9):e75113. [14]Mak H,Naba A,Varma S,et al.Ezrin phosphorylation on tyrosine 477 regulates invasion and metastasis of breast cancer cells[J].BMC Cancer,2012(12):82. [15]Jarvinen TA,Pelto-Huikko M,Holli K,et al Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer[J].Am J Pathol,2000,156(1):29-35. [16]Itoh M,Iwamoto T,Matsuoka J,et al.Estrogen receptor(ER)mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers[J].Breast Cancer Res Treat,2014,143(2):403-409. [17]Aleskandarany MA,Green AR,Benhasouna AA,et al.Prognosis value of proliferation assay in the luminal,HER2-positive,and triple-negative biologic classes of breast cancer[J].Breast Cancer Res,2012(14):R3. [18]Falck AK,Bendahl PO,Chebil G,et al.Biomarker expression and St Gallen molecular subtype classification in primary tumours,synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up[J].Breast Cancer Res Treat,2013,140(1):93-104. [19]黄小娥.Her-2蛋白表达与乳腺癌预后关系的相关性研究[J].中国现代医生杂志,2011,35(10):39-40. [20]秦颖,张同先.青年乳腺癌临床病理特点分子分型及预后分析[J].中国肿瘤临床,2014,14(4):231-236.

相似文献/References:

[1]董 云.SPECT/CT 双时相99mTc- MIBI断层显像 在乳腺癌诊断中的应用[J].医学信息,2018,31(05):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
　DONG Yun.Application of SPECT/CT Dual-phase 99mTc-MIBI Tomography in the Diagnosis of Breast Cancer[J].Journal of Medical Information,2018,31(21):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
[2]张 虎,张 涛,徐 芳,等.MRI在乳腺癌诊治中的研究进展[J].医学信息,2022,35(10):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
　ZHANG Hu,ZHANG Tao,XU Fang,et al.Research Progress of MRI in Diagnosis and Treatment of Breast Cancer[J].Journal of Medical Information,2022,35(21):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
[3]李建辉,祝旭龙.乳腺癌的治疗管理——把好生活质量关[J].医学信息,2018,31(13):1.[doi:10.3969/j.issn.1006-1959.2018.13.001]
[4]杨玉峰,李 强,曲国红,等.乳腺癌术前巴德枪穿刺检测ER、PR的临床研究[J].医学信息,2018,31(13):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
　YANG Yu-feng,LI Qiang,QU Guo-hong,et al.Clinical Study on Preoperative ER and PR Detection of Bard Gun Puncture in Breast Cancer[J].Journal of Medical Information,2018,31(21):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
[5]刘雪静,路 红,徐熠琳,等.乳腺影像与容积导航技术初步应用的临床分析[J].医学信息,2022,35(11):161.[doi:10.3969/j.issn.1006-1959.2022.11.043]
　LIU Xue-jing,LU Hong,XU Yi-lin,et al.Clinical Analysis of the Preliminary Application of Breast Imaging and Volume Navigation Technology[J].Journal of Medical Information,2022,35(21):161.[doi:10.3969/j.issn.1006-1959.2022.11.043]
[6]刘在波,修文娟.背阔肌皮瓣联合假体在乳腺癌改良根治术后乳房重建中的应用[J].医学信息,2019,32(02):127.[doi:10.3969/j.issn.1006-1959.2019.02.036]
　LIU Zai-bo,XIU Wen-juan.Application of Latissimus Dorsi Flap Combined with Prosthesis in Breast Reconstruction after Modified Radical Mastectomy for Breast Cancer[J].Journal of Medical Information,2019,32(21):127.[doi:10.3969/j.issn.1006-1959.2019.02.036]
[7]孟庆国,王佳雪,王斯佳.马来酸吡咯替尼对乳腺癌术后患者心脏功能的影响[J].医学信息,2019,32(02):152.[doi:10.3969/j.issn.1006-1959.2019.02.045]
　MENG Qing-guo,WANG Jia-xue,WANG Si-jia.Effect of Pyrrolidine Maleate on Cardiac Function in Patients after Breast Cancer Operation[J].Journal of Medical Information,2019,32(21):152.[doi:10.3969/j.issn.1006-1959.2019.02.045]
[8]刘 曼,厉玛倩倩,徐润润,等.延续性护理对乳腺癌术后化疗患者生活质量与 健康知识水平的影响[J].医学信息,2018,31(16):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
　LIU Man,LIMA Qian-qian,XU Run-run,et al.Effect of Continuous Nursing on Quality of Life and Health Knowledge of Postoperative Chemotherapy Patients with Breast Cancer[J].Journal of Medical Information,2018,31(21):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
[9]满枋霖,葛俊宏,林晓月,等.p21活化激酶在乳腺癌中的作用研究[J].医学信息,2019,32(06):35.[doi:10.3969/j.issn.1006-1959.2019.06.013]
　MAN Fang-lin,GE Jun-hong,LIN Xiao-yue,et al.The Role of p21 Activated Kinase in Breast Cancer[J].Journal of Medical Information,2019,32(21):35.[doi:10.3969/j.issn.1006-1959.2019.06.013]
[10]张天竺,宁 勇.长链非编码RNA调控乳腺癌发生发展的研究进展[J].医学信息,2019,32(12):40.[doi:10.3969/j.issn.1006-1959.2019.12.014]
　ZHANG Tian-zhu,NING Yong.Advances in Research on Long-chain Non-coding RNA Regulation of Breast Cancer Development[J].Journal of Medical Information,2019,32(21):40.[doi:10.3969/j.issn.1006-1959.2019.12.014]

更新日期/Last Update: 2019-11-01